Payment overview · 2025
General Payments
$1,310.30
53 reported records · 10 companies
Healthcare provider profile · identity verified
Ricardo E. Saca, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHINO, CA · NPI 1619072774
Verified facts
What the public records show
CMS Open Payments records show Ricardo E. Saca, M.D. received $1,310.30 in general payments during 2025 across 53 reported records.
Neurocrine BioSciences, Inc. accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $364.08 | 27.8% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $229.70 | 17.5% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $159.58 | 12.2% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $148.98 | 11.4% | 9 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $107.23 | 8.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.32 | 7.0% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $90.00 | 6.9% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $54.15 | 4.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.96 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.30 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,310.30 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $364.08 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $214.20 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $159.58 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $148.98 | 9 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $107.23 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.32 | 5 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $90.00 | 3 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $90.00 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $54.15 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $34.96 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $30.30 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 38 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 732 | 254 |
| Alendronate Sodium | Alendronate Sodium | 599 | 222 |
| Losartan Potassium | Losartan Potassium | 534 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 135 |
| Simvastatin | Simvastatin | 383 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 347 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 101 |
| Metformin Hcl | Metformin Hcl | 327 | 114 |
| Benazepril Hcl | Benazepril Hcl | 290 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 80 |
| Omeprazole | Omeprazole | 239 | 106 |
| Azithromycin | Azithromycin | 201 | 161 |
| Ibuprofen | Ibuprofen | 199 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 70 |
| Lisinopril | Lisinopril | 191 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 50 |
| Gabapentin | Gabapentin | 158 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 55 |
| Furosemide | Furosemide | 153 | 64 |
| Carvedilol | Carvedilol | 149 | 52 |
| Humalog Kwikpen U-100 | Insulin Lispro | 148 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 83 |
| Donepezil Hcl | Donepezil Hcl | 123 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 44 |
| Finasteride | Finasteride | 116 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 109 | 36 |
| Eliquis | Apixaban | 100 | 38 |
| Glipizide | Glipizide | 94 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 89 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 26 |
| Potassium Chloride | Potassium Chloride | 80 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 29 |
| Alprazolam | Alprazolam | 77 | 27 |
| Atenolol | Atenolol | 75 | 23 |
| Glimepiride | Glimepiride | 75 | 28 |
| Cephalexin | Cephalexin | 73 | 55 |
| Irbesartan | Irbesartan | 72 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 36 |
| Sildenafil Citrate | Sildenafil Citrate | 68 | 18 |
| Famotidine | Famotidine | 61 | 27 |
| Jardiance | Empagliflozin | 60 | 16 |
| Nifedipine Er | Nifedipine | 60 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 50 |
| Ciclopirox | Ciclopirox | 58 | 46 |
| Montelukast Sodium | Montelukast Sodium | 57 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 32 |
| Prednisone | Prednisone | 55 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 21 |
| Prolia | Denosumab | 52 | 32 |
| Allopurinol | Allopurinol | 49 | 18 |
| Spironolactone | Spironolactone | 47 | 18 |
| Memantine Hcl | Memantine Hcl | 46 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 15 |
| Lovastatin | Lovastatin | 43 | 13 |
| Meloxicam | Meloxicam | 40 | 20 |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 27 |
| Naproxen | Naproxen | 36 | 19 |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Ozempic | Semaglutide | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 19 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Clotrimazole | Clotrimazole | 27 | 21 |
| Ramelteon | Ramelteon | 27 | 14 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 18 |
| Nystatin | Nystatin | 23 | 16 |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Gemtesa | Vibegron | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,310.30 · 53 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ARISTADA, ARISTADA INITIO, AUSTEDO XR, CAPLYTA, COBENFY, FREESTYLE LIBRE 3, INGREZZA, INVEGA SUSTENNA, LOREEV XR, REXULTI, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error